Camp4 Therapeutics Corp CAMP
Camp4 Therapeutics Corp (Nasdaq: CAMP) is a CNS/neurology/psychiatry drug developer. Its lead program, CMP-002, is in Pre-clinical for SYNGAP1-related disorder (developmental and epileptic encephalopathy). Its next catalyst on record is CMP-002: Initiation of Phase 1/2 clinical trial in SYNGAP1 (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CMP-002 — Initiation of Phase 1/2 clinical trial in SYNGAP1 (Q4 2026). 7 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CMP-002 | SYNGAP1-related disorder | RNA (siRNA/ASO/mRNA) | Pre-clinical |
| Other CNS/DEE discovery programs | other CNS indications | RNA (siRNA/ASO/mRNA) | Pre-clinical |
| GSK collaboration programs (RAP Platform) | beyond CNS | RNA (siRNA/ASO/mRNA) | Pre-clinical |
Recent results and decisions
- Nov 6, 2025positive CMP-001 Phase 1 SAD/MAD in 86 healthy volunteers: no serious AEs or AE discontinuations, dose-dependent PK; pharmacodynamic activity inconclusive.
CMP-001 demonstrated a favorable safety profile in both the SAD and MAD portions, with no serious adverse events or discontinuations due to adverse events.
Filing - Nov 6, 2025n/a Netherlands CCMO approved the Clinical Trial Application for a Phase 1b study of CMP-001 in OTC heterozygotes (ex-US regulator); company will seek a partner.
Received Clinical Trial Application (CTA) approval from the Central Committee on Research Involving Human Subjects (CCMO) in the Netherlands to initiate a Phase 1b study of CMP-001 in OTC heterozygotes.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.